PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?

Clin Genitourin Cancer. 2016 Feb;14(1):e115-8. doi: 10.1016/j.clgc.2015.09.011. Epub 2015 Sep 30.

¹ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
² The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
³ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD; Depatment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
⁴ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Depatment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
⁵ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: mgorin1@jhmi.edu.

No abstract available

Keywords: Bone metastases; DCFPyL; PET/CT; PSMA; Prostate cancer.

Publication types

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
Antigens, Surface
Radiopharmaceuticals
Urea
Sodium Fluoride
FOLH1 protein, human
Glutamate Carboxypeptidase II
Lysine
Technetium Tc 99m Medronate